Intellectual Property and Access to HIV/AIDS Treatment – Case Studies

Until now, India, Brazil and Thailand have been among the biggest generic ARV producers, both for their own people and for export. This production has been crucial for the supply of affordable treatment in the developing world. It has resulted in competition between producers, which has reduced the price of many ARVs from as much as US$15,000/year per person for a course of combination treatment to as little as US$150/year per person. How have recent outcomes of WTO or bilateral agreements changed the situation?

This entry was posted in Briefing Papers, English, French, Publications. Publication Topics: . Bookmark the permalink. Both comments and trackbacks are currently closed.
Doc Type